Infliximab is a chimeric monoclonal antibody (mAb) binding to tumor necrosis factor alpha (TNF-α), approved in chronic inflammatory diseases both in rheumatology—e.g., rheumatoid arthritis (RA) and ankylosing spondylitis (AS)—and in inflammatory bowel diseases (IBD)—e.g., Crohn’s disease (CD) or ulcerative colitis (UC). The gene discussed is TNF; the disease is inflammatory bowel disease.